This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
VAREX IMAGING (VREX) Misses Q1 Earnings Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -27.27% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing VAREX IMAGING (VREX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
VREX vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
VREX vs. LMAT: Which Stock Is the Better Value Option?
Implied Volatility Surging for Varex Imaging (VREX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Varex Imaging (VREX) stock based on the movements in the options market lately.
VAREX IMAGING (VREX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of 52.38% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biora Therapeutics, Inc. (BIOR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biora Therapeutics, Inc. (BIOR) delivered earnings and revenue surprises of -33.33% and 20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 21.21% and 97.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate VAREX IMAGING (VREX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
VAREX IMAGING (VREX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -71.74% and 16.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to face COVID-induced challenges and market pressure.
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.
Avantor (AVTR) to Improve Biopharma Supply Chain With New Site
by Zacks Equity Research
Avantor's (AVTR) new logistics hub in Westminster is intended to support growth of single-use businesses.
Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about NEOGEN (NEOG) given robust sales growth in the Food Safety business and impressive international performance.
Boston Scientific (BSX) New Buyouts Aid Amid COVID Resurgence
by Zacks Equity Research
Boston Scientific's (BSX) new acquisitions like Preventice, Farapulse and Lumenis Surgical, which closed in March, August and September of 2021, respectively, are contributing to its inorganic growth.
Alcon (ALC) on Track With Successful Global PRECISION1 Rollout
by Zacks Equity Research
Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).
CVS Health (CVS) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Robust performance by the Pharmacy Services and Health Care Benefits arms is driving the top line for CVS Health (CVS).
Hologic (HOLX) Reports New Findings on Breast Cancer Index
by Zacks Equity Research
Hologic's (HOLX) latest data on Breast Cancer Index demonstrates its effectiveness in predicting net benefit from extended endocrine therapy.
Here's Why You Should Hold on to Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.
Thermo Fisher (TMO) Completes Acquisition of Leading CRO
by Zacks Equity Research
Thermo Fisher's (TMO) acquisition of PPD is likely to bolster its Laboratory Products and Services arm.
NextGen's (NXGN) Integrated Platform Gets Adopted by Monmouth
by Zacks Equity Research
NextGen's (NXGN) comprehensive solution suite was adopted by Monmouth to better cater to patients' medical and dental needs.
QIAGEN (QGEN) Gets CE Mark for QuantiFERON SARS-CoV-2 Assay
by Zacks Equity Research
QIAGEN's (QGEN) QuantiFERON SARS-CoV-2 assay enables a comprehensive assessment of immunity developed by COVID-19 vaccines.
Change Healthcare (CHNG) Cloud-Native PACS Now in Clinical Use
by Zacks Equity Research
The clinical use of Change Healthcare's (CHNG) cloud-native Stratus Imaging PACS is likely to enhance radiologists' productivity.
Here's Why You Should Retain IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) better-than-expected results and continued international growth in the third quarter.